MedTrace Logo

Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects

NCT05212259 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2022-11-30

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-controlled, Parallel Design Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion \& Joint Discomfort in Healthy Subjects

Conditions

Interventions

DRUG

Collagen type II (40 mg/day)

4 capsules per day

DRUG

Collagen type II (80mg/day)

4 capsules per day

DRUG

Collagen type II (120 mg/day)

4 capsules per day

DRUG

Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)

4 capsules per day

DRUG

Placebo

4 capsules per day

Sponsors & Collaborators

  • Vedic Lifesciences Pvt. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-10
Primary Completion
2023-09-15
Completion
2023-09-15

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212259 on ClinicalTrials.gov